Profile data is unavailable for this security.
About the company
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The Company's Connected Intelligence delivers insights enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission critical information, technology solutions and real-world insights and services to life science clients. Research & Development Solutions primarily serves biopharmaceutical clients, provides outsourced clinical research and clinical trial services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market.
- Revenue in USD (TTM)15.07bn
- Net income in USD1.36bn
- Incorporated2016
- Employees87.00k
- LocationIQVIA Holdings Inc2400 ELLIS ROADDURHAM 27703United StatesUSA
- Phone+1 (919) 998-2000
- Fax+1 (302) 636-5454
- Websitehttps://ir.iqvia.com/
Mergers & acquisitions
| Acquired company | IQV:NYQ since announced | Transaction value |
|---|---|---|
| Open Applications Consulting Ltd | 7.10% | -- |
| Bitac Map SL | 3.57% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. | 2.00bn | -332.08m | 20.29bn | 2.10k | -- | -- | -- | 10.13 | -2.71 | -2.71 | 15.78 | -1.73 | 0.5552 | 2.85 | 11.67 | 953,969.10 | -9.20 | -26.56 | -11.86 | -32.77 | 83.95 | 83.66 | -16.58 | -94.26 | 3.07 | -1.37 | 1.27 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| ICON PLC | 8.23bn | 683.12m | 25.91bn | 41.10k | 38.02 | 2.75 | 20.35 | 3.15 | 8.24 | 8.24 | 99.33 | 114.08 | 0.4795 | -- | 2.92 | 200,291.60 | 3.98 | 3.93 | 4.80 | 4.80 | 29.67 | 28.91 | 8.30 | 7.37 | -- | 3.48 | 0.2706 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| DuPont de Nemours Inc | 11.98bn | 404.00m | 33.31bn | 24.00k | 91.18 | 1.41 | 20.76 | 2.78 | 0.8736 | 0.8126 | 27.12 | 56.41 | 0.3036 | 3.37 | 4.99 | 499,208.30 | 1.12 | 0.3709 | 1.24 | 0.468 | 35.15 | 35.69 | 3.70 | 1.97 | 1.61 | 6.24 | 0.2446 | 414.03 | -7.29 | -11.79 | -51.19 | 11.24 | -30.66 | -20.59 |
| Gartner Inc | 5.97bn | 797.23m | 33.55bn | 20.29k | 43.02 | 47.07 | 33.86 | 5.62 | 10.05 | 10.05 | 75.24 | 9.18 | 0.7915 | -- | 3.80 | 295,054.30 | 10.57 | 8.24 | 19.95 | 14.76 | 67.72 | 67.55 | 13.35 | 12.20 | -- | 13.10 | 0.7738 | -- | 7.87 | 8.24 | 9.24 | 49.78 | -4.06 | -- |
| Biogen Inc | 9.66bn | 1.17bn | 33.73bn | 7.57k | 28.95 | 2.22 | 19.87 | 3.49 | 8.00 | 8.00 | 66.40 | 104.48 | 0.3777 | 1.27 | 4.80 | 1,276,499.00 | 4.56 | 12.53 | 5.20 | 14.83 | 75.03 | 81.84 | 12.08 | 26.93 | 1.32 | 3.78 | 0.3007 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Iqvia Holdings Inc | 15.07bn | 1.36bn | 38.76bn | 87.00k | 29.03 | 6.11 | 15.54 | 2.57 | 7.33 | 7.33 | 81.34 | 34.82 | 0.5761 | -- | 4.64 | 173,206.90 | 5.19 | 3.24 | 6.93 | 4.07 | 35.03 | 34.32 | 9.01 | 6.03 | -- | 3.19 | 0.6809 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
| Moderna Inc | 5.15bn | -5.97bn | 53.67bn | 5.60k | -- | 4.18 | -- | 10.41 | -15.66 | -15.66 | 13.51 | 33.46 | 0.2523 | 7.78 | 8.24 | 920,178.60 | -29.22 | 20.95 | -34.13 | 29.51 | 22.43 | -- | -115.82 | 32.10 | 3.91 | -- | 0.0429 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 20.27m | 11.13% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 10.85m | 5.96% |
| Harris Associates LPas of 31 Mar 2024 | 10.14m | 5.57% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 7.96m | 4.37% |
| AllianceBernstein LPas of 31 Mar 2024 | 4.22m | 2.32% |
| Geode Capital Management LLCas of 31 Mar 2024 | 4.16m | 2.28% |
| Lazard Asset Management LLCas of 31 Mar 2024 | 3.26m | 1.79% |
| Canada Pension Plan Investment Boardas of 31 Mar 2024 | 3.19m | 1.75% |
| Farallon Capital Management LLCas of 31 Mar 2024 | 2.84m | 1.56% |
| Longview Partners LLPas of 31 Mar 2024 | 2.52m | 1.39% |
